{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:59:39Z","timestamp":1777539579478,"version":"3.51.4"},"reference-count":82,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,8,13]],"date-time":"2018-08-13T00:00:00Z","timestamp":1534118400000},"content-version":"vor","delay-in-days":43,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hemodialysis International"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic hepatitis C virus (HCV) infection is a major global health problem affecting 3\u20135 million people in the United States and over 100 million worldwide. Chronic HCV infection, which can lead to cirrhosis and hepatocellular carcinoma, also results in numerous other complications, including impairment of renal function. Because HCV is most often transmitted via parenteral exposure to blood or blood products, patients with end\u2010stage renal disease (ESRD) treated with hemodialysis are at particular risk for infection. Historically, the medications available to treat HCV infection in these patients had significant side effects and were not particularly effective in generating a sustained virologic response. Since 2011, a number of direct\u2010acting antiviral therapies have emerged that can lead to virological cure in the vast majority of patients, with low pill burden and few side effects. Here, we describe the biology and pathophysiology of HCV infection, and summarize current information on new therapies, with a particular focus on their application in patients with chronic kidney disease including ESRD.<\/jats:p>","DOI":"10.1111\/hdi.12672","type":"journal-article","created":{"date-parts":[[2018,8,14]],"date-time":"2018-08-14T05:20:50Z","timestamp":1534224050000},"page":"297-307","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Hepatitis C virus infection in patients with end\u2010stage renal disease"],"prefix":"10.1111","volume":"22","author":[{"given":"John","family":"Wigneswaran","sequence":"first","affiliation":[{"name":"DaVita Rx, Inc. Coppell Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Van Wyck","sequence":"additional","affiliation":[{"name":"DaVita, Inc. Denver Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Pegues","sequence":"additional","affiliation":[{"name":"Hospital of the University of Pennsylvania Philadelphia Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Gholam","sequence":"additional","affiliation":[{"name":"Liver Center of Excellence University Hospitals of Cleveland Cleveland Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allen R.","family":"Nissenson","sequence":"additional","affiliation":[{"name":"DaVita, Inc. Denver Colorado USA"},{"name":"David Geffen School of Medicine University of California Los Angeles California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,8,13]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.7326\/M13-1133"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(05)70216-4"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510310332"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.36389"},{"key":"e_1_2_10_6_1","first-page":"3","article-title":"Risk factors for the transmission of hepatitis C","volume":"24","author":"Zeuzem S","year":"1996","journal-title":"J Hepatol."},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00649.x"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006070736"},{"key":"e_1_2_10_9_1","first-page":"1426","volume-title":"Principles and Practice of Infectious Diseases","author":"Curry M","year":"2005"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2523562"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2496467"},{"key":"e_1_2_10_12_1","first-page":"1529","article-title":"HCV\u2010genotypes: A review on their origin, global status, assay system, pathogenecity and response to treatment","volume":"57","author":"Irshad M","year":"2010","journal-title":"Hepatogastroenterology."},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13012"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i44.7896"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13022"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29505"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.07916"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1159\/000333772"},{"key":"e_1_2_10_19_1","first-page":"446","article-title":"Hepatitis C virus\u2010related kidney disease: Various histological patterns","volume":"74","author":"Sumida K","year":"2010","journal-title":"Clin Nephrol."},{"key":"e_1_2_10_20_1","unstructured":"American Association for the Study of Liver Diseases Infectious Diseases Society of America. Recommendations for testing managing and treating hepatitis C.2017. Available from:http:\/\/www.hcvguidelines.org\/unique-populations\/renal-impairment(accessed date: April 18 2018)."},{"key":"e_1_2_10_21_1","unstructured":"SenekaP SolidC BovitzT GuoH CollinsA ArduinoJ.Hepatitis C and renal disease: Differences in patient characteristics and clinical outcomes in the United States. Paper presented at: Annual association for the study of liver diseases: The liver meeting 2015 San Francisco CA."},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-009-9576-3"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.5402\/2013\/159760"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh895"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2012.01633.x"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000100127.54107.57"},{"key":"e_1_2_10_27_1","unstructured":"United States Renal Data System. USRDS 2003 Annual data report: Atlas of end\u2010stage renal diseases in the United States. National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases 2003 Bethesda MD."},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00803.x"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajkd.2003.07.016"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043545"},{"key":"e_1_2_10_31_1","first-page":"345","article-title":"Hepatitis C virus infection as a risk factor for increased aortic stiffness and cardiovascular events in dialysis patients","volume":"21","author":"Oyake N","year":"2008","journal-title":"J Nephrol."},{"key":"e_1_2_10_32_1","first-page":"1","article-title":"Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV\u2010related chronic disease. Centers for Disease Control and Prevention","volume":"47","year":"1998","journal-title":"MMWR Recomm Rep."},{"key":"e_1_2_10_33_1","first-page":"1","volume":"19","author":"NIH Consensus Statement on Management of Hepatitis C: 2002","year":"2002","journal-title":"NIH Consens State Sci Statements."},{"key":"e_1_2_10_34_1","unstructured":"Centers for Disease Control and Prevention. Testing recommendations for hepatitis C virus infection.2012."},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27950"},{"key":"e_1_2_10_36_1","unstructured":"ESRD program interpretive guidance\u2013\u2013Version 1.1. Available from:https:\/\/www.cms.gov\/Medicare\/Provider\u2010Enrollment\u2010and\u2010Certification\/GuidanceforLawsAndRegulations\/Downloads\/esrdpgmguidance.pdfCenters for Medicare & Medicais Services ed. 2008 (accessed May 24 2018)."},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-5-201309030-00672"},{"key":"e_1_2_10_38_1","first-page":"1","article-title":"Recommendations for preventing transmission of infections among chronic hemodialysis patients","volume":"50","year":"2001","journal-title":"MMWR Recomm Rep."},{"key":"e_1_2_10_39_1","first-page":"362","article-title":"Testing for HCV infection: An update of guidance for clinicians and laboratorians","volume":"62","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"e_1_2_10_40_1","unstructured":"Decision memorandum for screening for hepatitis C virus (HCV) in adults. Available from:https:\/\/www.cms.gov\/medicare\u2010coverage\u2010database\/details\/nca\u2010decision\u2010memo.aspx?NCAId=272Centers for Medicare & Medicais Services ed. 2014 (accessed May 24 2018)."},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/12.7.1394"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2001.21294"},{"key":"e_1_2_10_43_1","unstructured":"Centers for Disease Control and Prevention. CDC urging dialysis providers and facilities to assess and improve infection control practices to stop hepatitis C virus transmission in patients undergoing hemodialysis.2016."},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6450a5"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.07.009"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(03)00828-X"},{"key":"e_1_2_10_47_1","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1681\/ASN.V9122344","article-title":"Pharmacokinetics of alphaIFN\u20102b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: Clinical implications","volume":"9","author":"Rostaing L","year":"1998","journal-title":"J Am Soc Nephrol."},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01780.x"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/14.11.2704"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1995.198"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1159\/000355615"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00349-9"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12899"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0817-y"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704053"},{"key":"e_1_2_10_56_1","unstructured":"Mavyret Full Prescribing Information. North Chicago (IL): Abbvie;2017."},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1837"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2012.02771.x"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir076"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.11.022"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-0456"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.01038.x"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.11.002"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.4103\/1319-2442.168602"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-015-3801-y"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00080.x"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12629"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.12.1271"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02510317"},{"key":"e_1_2_10_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12639"},{"key":"e_1_2_10_71_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194329"},{"key":"e_1_2_10_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/sdi.12640"},{"key":"e_1_2_10_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28156"},{"key":"e_1_2_10_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14396"},{"key":"e_1_2_10_75_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1505074"},{"key":"e_1_2_10_76_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2015010023"},{"key":"e_1_2_10_77_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2012.03.015"},{"key":"e_1_2_10_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03280.x"},{"key":"e_1_2_10_79_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29258"},{"key":"e_1_2_10_80_1","unstructured":"Management of hepatitis C in late\u2010stage CKD patients: Who how and when to treat?National Kidney Foundation: Professional Education Resource Center 2017. Available from:https:\/\/education.kidney.org\/content\/management-hepatitis-c-late-stage-ckd-patients-who-how-and-when-treat#group-tabs-node-course-default1(accessed date: April 18 2018)."},{"key":"e_1_2_10_81_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1705221"},{"key":"e_1_2_10_82_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14381"},{"key":"e_1_2_10_83_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.07940716"}],"container-title":["Hemodialysis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhdi.12672","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hdi.12672","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:26:25Z","timestamp":1695011185000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hdi.12672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":82,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1111\/hdi.12672"],"URL":"https:\/\/doi.org\/10.1111\/hdi.12672","archive":["Portico"],"relation":{},"ISSN":["1492-7535","1542-4758"],"issn-type":[{"value":"1492-7535","type":"print"},{"value":"1542-4758","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"2018-03-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}